One To Watch

Viking Therapeutics

A clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, with a lead dual GLP-1/GIP receptor agonist program.

Company Overview

A clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, with a lead dual GLP-1/GIP receptor agonist program. Viking Therapeutics leverages its expertise in metabolism to develop first-in-class and best-in-class therapeutics designed to improve patients' lives. The company's primary focus centers on VK2735, a dual agonist targeting the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for obesity treatment.

Headquarters and Global Presence

Viking Therapeutics is headquartered in San Diego, California, and operates as a focused U.S.-based company with approximately 53-56 employees. The company maintains a concentrated presence in the United States while establishing strategic manufacturing partnerships internationally to support its clinical programs.

Founding and History

Viking Therapeutics was incorporated in September 2012 and established its initial foundation through a relationship with Ligand Pharmaceuticals, which provided critical early resources including intellectual property and infrastructure support. This partnership enabled Viking to prioritize research and development in novel metabolic therapies from its inception.

Therapy Areas and Focus

The company focuses exclusively on metabolic and endocrine disorders, with obesity as its primary therapeutic target. Viking's strategy centers on addressing the significant unmet medical need in weight management through novel receptor agonist approaches. The company's expertise in metabolism positions it to develop therapies that target fundamental pathways regulating energy balance and glucose homeostasis.

Technology Platforms and Modalities

Viking's technology platform is built around dual receptor agonism, specifically targeting the GLP-1 and GIP pathways simultaneously. This approach leverages the complementary mechanisms of these incretin hormones to potentially achieve superior weight loss and metabolic benefits compared to single-target therapies. The company's peptide-based therapeutic modality focuses on optimizing pharmacokinetics and patient convenience through subcutaneous administration.

Key Pipeline and Programs

VK2735, Viking's lead program, is a dual GLP-1/GIP receptor agonist currently in Phase III development for obesity treatment. The company has completed patient enrollment for both the VANQUISH-1 and VANQUISH-2 registration-enabling trials, with pivotal results expected in 2027. VK2735 represents Viking's primary clinical asset and the foundation of its commercial strategy in the competitive obesity therapeutics market.

Key Personnel

Brian Lian serves as Chief Executive Officer and President of Viking Therapeutics, leading the company's strategic direction and clinical development programs. The management team also includes specialized commercial leadership, with the recent addition of a Chief Commercial Officer bringing over two decades of biopharmaceutical experience in cardiometabolic markets.

Strategic Partnerships

Viking has established a significant $150 million multi-year strategic partnership with CordenPharma to support the development and commercialization of VK2735. This collaboration leverages CordenPharma's expertise in peptide drug substance manufacturing, sterile injectables, and oral solid dosage forms to support commercial-scale production. The partnership positions Viking to meet anticipated commercial demand while maintaining supply chain control for its lead program.

FAQ Section

Viking must demonstrate that VK2735 can differentiate itself in the highly competitive GLP-1 obesity market dominated by established players like Novo Nordisk and Eli Lilly. The company's success depends on proving superior efficacy, safety, or convenience compared to existing dual-target competitors entering the same space.

Dual GLP-1/GIP agonism potentially offers superior weight loss compared to GLP-1-only therapies by leveraging complementary pathways that regulate appetite, gastric emptying, and glucose metabolism. This approach may achieve greater efficacy while potentially improving tolerability through optimized receptor activation patterns.

Viking is positioning VK2735 as a potentially best-in-class dual agonist with optimized pharmacokinetic properties for subcutaneous administration. The company's focus on metabolic expertise and strategic manufacturing partnerships aims to deliver competitive clinical outcomes while ensuring scalable commercial supply.

VK2735 represents Viking's entire commercial future as a single-asset company targeting the multi-billion dollar obesity market. Success in the ongoing Phase III trials would establish Viking as a significant player in next-generation obesity therapeutics, while failure would require a fundamental strategic pivot.

Viking is exclusively focused on metabolic and endocrine disorders, with obesity as the primary indication for its lead program VK2735. The company's concentrated approach reflects its specialized expertise in metabolism rather than a diversified pipeline strategy.

Viking is in late-stage clinical development with both Phase III registration trials for VK2735 fully enrolled and ongoing. The company is transitioning from a clinical-stage to a pre-commercial company, with pivotal readouts expected in 2027 that will determine its path to market authorization.

Key near-term catalysts and risks for Viking include:

Phase III trial readouts for VK2735 expected in 2027, which will determine regulatory pathway success
Competitive positioning against other dual GLP-1/GIP agonists reaching market simultaneously
Manufacturing scale-up execution through the CordenPharma partnership to support potential commercial launch
Capital requirements and funding runway to reach commercialization without dilutive financing

Want to Update your Company's Profile?